Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 2224-2231

  Aruga, Atsushi ^a   Takeshita, Nobuhiro ^a   Kotera, Yoshihito ^a   Okuyama, Ryuji ^a   Matsushita, Norimasa ^a   Ohta, Takehiro ^a   Takeda, Kazuyoshi ^b   Yamamoto, Masakazu ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER VACCINE; DEP DOMAIN CONTAINING 1; HLA A ANTIGEN; INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; LYMPHOCYTE ANTIGEN 6 COMPLEX LOCUS K; TTK PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIARY TRACT CANCER; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; LYMPHOCYTOPENIA; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

AGED; ANTIGENS, NEOPLASM; BILIARY TRACT NEOPLASMS; CANCER VACCINES; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLOW CYTOMETRY; HLA-A24 ANTIGEN; HUMANS; INTERFERON-GAMMA; LYMPHOPENIA; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TESTIS; TIME FACTORS; TREATMENT OUTCOME; VACCINATION; VACCINES, SUBUNIT;

EID: 84877098842     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3592     Document Type: Article

References (27)

1. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in Japan. Br J Cancer 2010;103:469-74.
2. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
3. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non-small cell lung cancer. Clin Cancer Res 2007;13(15Suppl):4652s-4s. (Pubitemid 47219742)
4. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27.
5. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012;18:3686-96.
6. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, et al. Cancer-testis antigen lymphocyte anteigen 6 complex lolus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007;67:11601-11.
7. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007;98:1803-8. (Pubitemid 47489730)
8. Mizukami Y, Kono K, Daigo Y, Rakano A, Tsunoda T, Kawaguchi Y, et al. Detection of novel cancer-testis antigen-speci fic T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008;99:1448-54. (Pubitemid 351761737)
9. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 2007;26:6448-55. (Pubitemid 47494219)
10. Muragaki Y, Maruyama T, Iseki H, Tanaka M, Shinohara C, Takakura K, et al. Phase I/II trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for initially-diagnosed Glioblastoma. J Neuro Surg 2011;115:248-55.
11. Shimizu K, Kotera Y, Aruga A, Takeshita N, Takasaki K, Yamamoto M. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2012;19:171-8.
12. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008;14:3098-104.
13. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009;100:1502-9.
14. Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancertestis antigens. J Transl Med 2012;10:141.
15. Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, et al. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol 2012;42:591-600.
16. Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010;101:433-9.
17. Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto M. Phase I trial of Wilm's tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res 2012;32:2263-70.
18. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010;59:1001-9.
19. Koike N, Pilon-Thomas S, Mule JJ. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother 2008;31:402-12. (Pubitemid 351595163)
20. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2012;118:4853-62.
21. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012;30:837-42.
22. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008;333:167-79.
23. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiechi D, Lyerly DH, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2010;112:610-8.
24. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
25. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
26. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
27. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011;17:3520-6.